Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Low cost drug helps reduce deaths, repeat heart attacks


Reviparin is simple, effective therapy for heart attack patients worldwide

A major Canadian-led global study has found that an inexpensive anti-blood-clotting drug significantly reduces death and repeat heart attacks without increasing the risk of stroke. The study is of significance to patients in all countries, including developing countries where access to high-tech treatments for cardiovascular problems may be limited.

The CREATE randomized trial was initiated and coordinated in Canada and enrolled more than 15,500 people in China, India and Pakistan. Heart attack patients were given Reviparin, a low molecular weight heparin, or a placebo, twice daily for seven days.

The four-year study showed that the risk of deaths, heart attacks and strokes were reduced by about one-sixth. This means that treating 1,000 patients for a week would prevent about 15 to 20 individuals from dying or suffering a new heart attack. The study also showed that the benefits were greater, the earlier the treatment was used after the onset of symptoms. In those who were treated within two hours of symptom onset, the death rate was lowered by about 30 per cent.

The study was presented today at the Scientific Sessions of the American Heart Association conference in New Orleans by co-investigators Dr. Salim Yusuf and Dr. Shamir Mehta of the Population Health Research Institute at Hamilton Health Sciences and McMaster University. Dr. Yusuf is a professor of medicine at the Michael G. DeGroote School of Medicine at McMaster University, director of the Population Health Research Institute and holds an endowed chair of the Heart and Stroke Foundation of Ontario. Dr. Mehta is an associate professor of medicine at the Michael G. DeGroote School of Medicine, member of the Population Health Research Institute and a clinician scientist with the Canadian Institutes of Health Research.

"Reviparin is a simple and relatively inexpensive anti-thrombotic therapy, which can be used in both developed and developing countries to reduce mortality for acute myocardial infarction," said Dr. Yusuf. "It is more affordable than newer anti-thrombotics, simple to use and of benefit in addition to the broad range of therapies of proven and established value. It is the only treatment for a heart attack that has been convincingly demonstrated to reduce mortality in a single study over the last decade." Dr. Mehta said: "The reduction in mortality with Reviparin is truly remarkable since no other drug in this class has shown similar benefits and the fact the drug was tested on top of already proven therapies."

About 15.5 million people die worldwide from cardiovascular deaths each year and about half of these are due to acute myocardial infarction, with the majority occurring in low and middle-income countries, Dr. Yusuf noted. "Low cost therapies are obviously more invaluable than expensive ones," he said. "This therapy could be used not only in wealthy countries, but also in small medical centres in low and middle income countries. It has the potential to benefit more than a million individuals annually."

In a companion study, also presented today at the American Heart Association meeting, Drs. Mehta and Yusuf evaluated the role of high dose glucose-insulin-potassium (GIK) solution in 20,000 patients. The solution is thought to preserve heart muscle and prevent it from dying during the acute stages of a heart attack.

The study results show that GIK had a neutral effect, but the authors wonder whether a solution that had a lower glucose concentration may be of benefit. "It is important to conduct large studies of promising agents to determine whether or not they are of value," said Dr. Mehta. "While demonstrating that something is of benefit is wonderful, reliably excluding agents are not helpful is equally important as it will avoid their unnecessary use and associated costs. This is particularly important for therapies such as GIK that may never otherwise be studied because they are of no commercial value but have the promise to help many thousands of lives."

Dr. John Kelton, dean of the Michael G. DeGroote School of Medicine and dean and vice-president, Faculty of Health Sciences, McMaster University, said: "This important study represents one of the first in many years that is bringing in a new drug that will produce a significant reduction in deaths from heart attack. Perhaps more importantly, I see a future treatment given by ambulance attendants where a person suspected of having a heart attack is given an aspirin and an injection of this heparin-like drug. The lives saved in Canada and around the world would be dramatic."

Mr. Murray Martin, President and CEO of Hamilton Health Sciences of Hamilton, said: "Part of our mission as an academic teaching hospital is to advance health care through education and research. We commend Dr. Yusuf and Dr. Mehta for their leadership and commitment to investigating best practices and finding better ways to help people around the world deal with important health issues."

Shelly Easton | EurekAlert!
Further information:

More articles from Studies and Analyses:

nachricht Rutgers-led innovation could spur faster, cheaper, nano-based manufacturing
14.02.2018 | Rutgers University

nachricht New study from the University of Halle: How climate change alters plant growth
12.01.2018 | Martin-Luther-Universität Halle-Wittenberg

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Space observation with radar to secure Germany's space infrastructure

Satellites in near-Earth orbit are at risk due to the steady increase in space debris. But their mission in the areas of telecommunications, navigation or weather forecasts is essential for society. Fraunhofer FHR therefore develops radar-based systems which allow the detection, tracking and cataloging of even the smallest particles of debris. Satellite operators who have access to our data are in a better position to plan evasive maneuvers and prevent destructive collisions. From April, 25-29 2018, Fraunhofer FHR and its partners will exhibit the complementary radar systems TIRA and GESTRA as well as the latest radar techniques for space observation across three stands at the ILA Berlin.

The "traffic situation" in space is very tense: the Earth is currently being orbited not only by countless satellites but also by a large volume of space...

Im Focus: Researchers Discover New Anti-Cancer Protein

An international team of researchers has discovered a new anti-cancer protein. The protein, called LHPP, prevents the uncontrolled proliferation of cancer cells in the liver. The researchers led by Prof. Michael N. Hall from the Biozentrum, University of Basel, report in “Nature” that LHPP can also serve as a biomarker for the diagnosis and prognosis of liver cancer.

The incidence of liver cancer, also known as hepatocellular carcinoma, is steadily increasing. In the last twenty years, the number of cases has almost doubled...

Im Focus: Researchers at Fraunhofer monitor re-entry of Chinese space station Tiangong-1

In just a few weeks from now, the Chinese space station Tiangong-1 will re-enter the Earth's atmosphere where it will to a large extent burn up. It is possible that some debris will reach the Earth's surface. Tiangong-1 is orbiting the Earth uncontrolled at a speed of approx. 29,000 km/h.Currently the prognosis relating to the time of impact currently lies within a window of several days. The scientists at Fraunhofer FHR have already been monitoring Tiangong-1 for a number of weeks with their TIRA system, one of the most powerful space observation radars in the world, with a view to supporting the German Space Situational Awareness Center and the ESA with their re-entry forecasts.

Following the loss of radio contact with Tiangong-1 in 2016 and due to the low orbital height, it is now inevitable that the Chinese space station will...

Im Focus: Alliance „OLED Licht Forum“ – Key partner for OLED lighting solutions

Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP, provider of research and development services for OLED lighting solutions, announces the founding of the “OLED Licht Forum” and presents latest OLED design and lighting solutions during light+building, from March 18th – 23rd, 2018 in Frankfurt a.M./Germany, at booth no. F91 in Hall 4.0.

They are united in their passion for OLED (organic light emitting diodes) lighting with all of its unique facets and application possibilities. Thus experts in...

Im Focus: Mars' oceans formed early, possibly aided by massive volcanic eruptions

Oceans formed before Tharsis and evolved together, shaping climate history of Mars

A new scenario seeking to explain how Mars' putative oceans came and went over the last 4 billion years implies that the oceans formed several hundred million...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

New solar solutions for sustainable buildings and cities

23.03.2018 | Event News

Virtual reality conference comes to Reutlingen

19.03.2018 | Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

Latest News

For graphite pellets, just add elbow grease

23.03.2018 | Materials Sciences

Unique communication strategy discovered in stem cell pathway controlling plant growth

23.03.2018 | Agricultural and Forestry Science

Sharpening the X-ray view of the nanocosm

23.03.2018 | Physics and Astronomy

Science & Research
Overview of more VideoLinks >>>